Financial Disclosure Policy For Commenters Detailed In FDA Draft Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
The document, intended for industry reps, consumer associations and other stakeholders, explains how to secure a time slot for public portions of FDA meetings and “encourages” disclosure of financial relationships. The draft guidance is released shortly before the advisory committee on the safety of COX-2 inhibitors.